Clinical trial · no report yet · Phase 3
MajesTEC-9
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05572515 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 148 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 66 | |
| YouTube | 50 | |
| Podcasts | 28 | |
| X videos | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Teclistamab; Pomalidomide; Bortezomib; Dexamethasone; Carfilzomib
- Arms
- Teclistamab · Experimental
- Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd) · Experimental
- Enrollment
- 614
- Primary outcomes
- Part 1: Progression-free Survival (PFS)
- Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
- Sponsor
- Janssen Research & Development, LLC
- Start
- Mar 29, 2023
- Primary completion
- Oct 13, 2025
- Results posted
- No
- Registry record
- NCT05572515 · updated Apr 13, 2026
Publications
linked from the registry- Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, Botta C, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegard M, Wang D, Pei L, Wroblewski S, Aries IM, Quijano Carde NA, Perova T, de Jager T, Yeh TM, Vanquickelberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O; MajesTEC-9 Trial Investigators. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. N Engl J Med. 2026 Jul 30;395(5):440-453. doi: 10.1056/NEJMoa2603870. Epub 2026 May 29. PubMed 42212933